Study of Durysta Eye Implant in Adults with Open-Angle Glaucoma or Ocular Hypertension to Reduce Eye Surface Inflammation

What this Trial Is About

Researchers are evaluating whether reducing the use of topical eye medications by injecting a sustained release capsule called Durysta can decrease inflammation on the surface of the eye. This inflammation is measured by levels of caspase-1, a biomarker related to eye surface damage. The study focuses on adults with open-angle glaucoma or suspected glaucoma who use topical ocular hypotensive medications. Participants will receive a one-time injection of Durysta, which contains bimatoprost 10 micrograms, directly into the eye. After the injection, participants will be followed for three months to observe changes. The study does not involve any placebo or comparison groups and is open-label with no masking. During the study, researchers will measure changes in caspase-1 mRNA expression at baseline, one month, and three months after the injection. They will also assess corneal sensitivity, ocular pain using a visual analog scale, and corneal staining scores with the National Eye Institute grading system at the same time points. Participant adherence to medication and eye health will be monitored throughout the study period, which lasts three months in total.

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use